Michael Ehlers jumps a listing ship, turning to VC and startups as a damaged Biogen taps longtime vet Al Sandrock to take his place
Just a little more than 3 years after Michael Ehlers took the lead job as global head of R&D for the now deeply troubled Biogen, he’s jumping ship. And CEO Michel Vounatsos is naming CMO Al Sandrock, the architect of a deeply flawed pipeline strategy, as his replacement.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,800+ biopharma pros reading Endpoints daily — and it's free.